Results 201 to 210 of about 1,967,846 (356)

COVID-19 and Breast Cancer Prognosis: A Comparative Analysis of Disease-Free Survival Rates in Taiwan. [PDF]

Cancer Manag Res
Wang WT, Wu PS, Hu WC, Chou CP.
europepmc   +1 more source

Prognostic factors affecting disease-free survival rate following surgical resection of primary breast cancer

, 2009
Kohjiro Horita, Ai Yamaguchi, Kiyotaka Hirose, Makoto Ishida, Sakon Noriki, Yoshinori Imamura, M Fukuda   +6 more
openalex   +1 more source

Six year disease free survival after liver transplantation in a patient with T3 gallbladder carcinoma: case presentation and review of the literature [PDF]

, 2006
Jorge Ortiz, David J. Reich, Hoon Bae Joon, Óscar Núñez, Cosme Manzarbeitia   +4 more
openalex   +1 more source

LINC01116, a hypoxia‐lncRNA marker of pathological lymphangiogenesis and poor prognosis in lung adenocarcinoma

Molecular Oncology, EarlyView.
The LINC01116 long noncoding RNA is induced by hypoxia and associated with poor prognosis and high recurrence rates in two cohorts of lung adenocarcinoma patients. Here, we demonstrate that besides its expression in cancer cells, LINC01116 is markedly expressed in lymphatic endothelial cells of the tumor stroma in which it participates in hypoxia ...
Marine Gautier‐Isola, Rafael Lopes Goncalves, Marin Truchi, Caroline Lacoux, Célia Scribe, Hugo Cadis, Laetitia Guardini, Sophie Bekisz, Marius Ilié, Paul Hofman, Georges Vassaux, Bernard Mari, Roger Rezzonico   +12 more
wiley   +1 more source

The atherogenic index of plasma and triglyceride-glucose index as promising predictors of overall and disease-free survival in postoperative breast cancer patients. [PDF]

Front Endocrinol (Lausanne)
Chen Z, Luo M, Liu L, Cheng M, Gao H, Ma S.   +5 more
europepmc   +1 more source

A subset of MMR‐proficient colon cancers responds to neoadjuvant immunotherapy

Molecular Oncology, EarlyView.
Tan et al. reveal that a distinct subset of early‐stage pMMR colon cancers can respond to neoadjuvant immunotherapy. In the NICHE‐2 trial, responders (26%) were characterized by chromosomal instability, TP53 mutations, and proliferative cell‐cycle programs, whereas nonresponders showed metabolic and stromal reprogramming with TGF‐β‐driven ...
Eleonora Piumatti, Giovanni Germano, Pietro Paolo Vitiello, Alberto Bardelli   +3 more
wiley   +1 more source

Association between FOXP3 Expression and Disease-Free Survival in Triple Negative Breast Cancer. [PDF]

Iran J Pathol
Adhitama H, Suwardjo S, Dwianingsih EK, Aryandono T.   +3 more
europepmc   +1 more source

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

Molecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking   +43 more
wiley   +1 more source

Automatically quantifying spatial heterogeneity of immune and tumor hypoxia environment and predicting disease-free survival for patients with rectal cancer. [PDF]

Cancer Immunol Immunother
Chen S, Liu Z, Wang J, Zhang Z, Dekker A, Wee L, Kalendralis P, Sun Y, Tong T.   +8 more
europepmc   +1 more source

Disease-Free Survival is a Promising Surrogate for Overall Survival in Colorectal Cancer Studies [PDF]

JNCI: Journal of the National Cancer Institute, 2021
openaire   +2 more sources